0001178913-23-001109.txt : 20230323
0001178913-23-001109.hdr.sgml : 20230323
20230323073327
ACCESSION NUMBER: 0001178913-23-001109
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230316
FILED AS OF DATE: 20230323
DATE AS OF CHANGE: 20230323
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Darvish Nissim
CENTRAL INDEX KEY: 0001793602
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38807
FILM NUMBER: 23754476
MAIL ADDRESS:
STREET 1: C/O INNOVATE BIOPHARMACEUTICALS, INC.
STREET 2: 8480 HONEYCUTT ROAD, SUITE 120
CITY: RALEIGH
STATE: NC
ZIP: 27615
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Chemomab Therapeutics Ltd.
CENTRAL INDEX KEY: 0001534248
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 813676773
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: KIRYAT ATIDIM, BUILDING 7
CITY: TEL AVIV
STATE: L3
ZIP: 6158002
BUSINESS PHONE: 972-77-331-0156
MAIL ADDRESS:
STREET 1: KIRYAT ATIDIM, BUILDING 7
CITY: TEL AVIV
STATE: L3
ZIP: 6158002
FORMER COMPANY:
FORMER CONFORMED NAME: Anchiano Therapeutics Ltd.
DATE OF NAME CHANGE: 20180906
FORMER COMPANY:
FORMER CONFORMED NAME: BioCancell Ltd.
DATE OF NAME CHANGE: 20111104
4
1
zk2329427.xml
X0407
4
2023-03-16
0
0001534248
Chemomab Therapeutics Ltd.
CMMB
0001793602
Darvish Nissim
C/O CHEMOMAB THERAPEUTICS LTD.
KIRYAT ATIDIM, BUILDING 7
TEL AVIV
L3
6158002
ISRAEL
1
0
0
0
0
American Depositary Shares
1200
D
Option to Purchase American Depositary Shares
1.62
2023-03-16
4
A
0
6857
0
A
2033-03-21
American Depositary Shares
6857
6857
D
Option to Purchase American Depositary Shares
3.53
2022-03-07
4
A
0
6820
0
A
2032-03-07
American Depositary Shares
6820
6820
D
Option to Purchase American Depositary Shares
27.26
2021-04-19
4
A
0
11884
0
A
2031-04-19
American Depositary Shares
11884
11884
D
Option to Purchase American Depositary Shares
0.8
2016-10-28
4
A
0
10123
0
A
2017-10-27
American Depositary Shares
10123
10123
D
Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.
No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.
These options were granted as per the annual grant of options to directors. These options vest and become exercisable in their entirety on March 16, 2024, subject to the Reporting Person's continued service.
These options vested and became exercisable in their entirety on March 16, 2023. These options were granted as per the annual grant of options to directors.
These options vest and become exercisable in equal monthly installments over a 36 month period commencing on March 16, 2021, subject to the Reporting Person's continued service.
The options reported in this row have all vested and are exercisable as of the date hereof, subject to the Reporting Person's continued service.
/s/ Matthew Rudolph, Esq., Attorney-in-Fact for Nissim Darvish
2023-03-23